Mike Hernández - Concepedia

Author

Mike Hernández

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Hernandez, Mike, M Hernandez, M Hernández, M. Hernandez, M. Hernández, M.S. Gil Hernández, MICHAEL HERNANDEZ, MIKE HERNANDEZ, Maricarmen Hernández, Michael Hernandez

263

Publications

Citations

H-Index

127

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Anesthesiology and Surgical Oncology Research Group University of Colorado Denver University of Houston The University of Texas Health Science Center at Houston

About

Mike Hernández is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	34	2.4K
2	Health Sciences	11	11	1.5K
3	Public Health	8	8	263
4	Anesthesia	4	4	98
5	Nursing	2	2	59

Mike Hernández

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study Daniel R. Gomez, Chad Tang, Jianjun Zhang, Journal of Clinical Oncology	2019	1.2K
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study Daniel R. Gomez, George R. Blumenschein, J. Jack Lee, The Lancet Oncology First-line Systemic TherapyMedicineCancer ManagementBronchial NeoplasmCombined Modality Treatment	2016	1.1K
Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis Pierre Blanchard, Adam S. Garden, G. Brandon Gunn, Radiotherapy and Oncology	2016	223
Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience Maria E. Cabanillas, Steven G. Waguespack, Yulia Bronstein, The Journal of Clinical Endocrinology & Metabolism	2010	193
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes Terence T. Sio, Huei-Kai Lin, Qiuling Shi, International Journal of Radiation OncologyBiologyPhysics Patient-reported OutcomesRadiation MedicineRadiation TherapyMedicineOropharyngeal Cancer	2016	170
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy Sarah S. Mougalian, Mike Hernández, Xiudong Lei, JAMA Oncology	2015	157
Prospective Evaluation of the Nipple–Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer Jamie L. Wagner, Regina M. Fearmonti, Kelly K. Hunt, Annals of Surgical Oncology Surgical OncologyBreast OncologyMedicineProspective EvaluationRisk Reduction	2011	130
Intensity‐modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes Gary D. Lewis, Emma B. Holliday, Esengul Kocak–Uzel, Head & Neck	2015	127
Chylous Ascites After Post-Chemotherapy Retroperitoneal Lymph Node Dissection: Review of the M. D. Anderson Experience James G. Evans, Philippe E. Spiess, Ashish M. Kamat, The Journal of Urology	2006	116
Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies David S. Hong, Maria E. Cabanillas, Jennifer J. Wheler, The Journal of Clinical Endocrinology & Metabolism	2011	110

Page 1